JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

The Journal of Nuclear Medicine Vol. 15 No. 12 1110-1112
© 1974 by Society of Nuclear Medicine
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Citrin, D. L.
Right arrow Articles by Greig, W. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Citrin, D. L.
Right arrow Articles by Greig, W. R.

Clinical Evaluation of 99mTc-Labeled Monofluorophosphate: A Comparison with Ethane-Hydroxy-Diphosphonate

D. L. Citrin, R. G. Bessent and W. R. Greig

Royal Infirmary and Western Regional Hospital Board, Glasgow, Scotland

Correspondence: For reprints contact: D. L. Citrin, Dept. of Nuclear Medicine, Royal Infirmary, Glasgow G40 SF, Scotland.

ABSTRACT

In preliminary clinical studies a new bone-scanning agent, 99mTc-labeled monofluorophosphate (MFP), provided satisfactory visualization of bone tumors. Comparison of MFP with EHDP shows, however, that because of higher tumor/bone ratios, lower blood activities, and more rapid whole-body excretion, EHDP remains the agent of choice at present.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 1974 by the Society of Nuclear Medicine.